Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should somatostatin or gabexate be given for prophylaxis of pancreatitis in patients undergoing ERCP?

Nature Clinical Practice Gastroenterology & Hepatology volume 5, pages 14–15 (2008)Cite this article

boxed-textAndriulli A et al. (2007) Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 65: 624–632

Pharmacologic prophylaxis for post-ERCP pancreatitis is still of questionable benefit; however, a subgroup of high-risk patients might benefit from intravenous administration of somatostatin or gabexate

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Freeman ML and Guda NM (2004) Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59: 845–864

    Article  Google Scholar 

  2. Freeman ML et al. (2001) Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 54: 425–434

    Article  CAS  Google Scholar 

  3. Manes G et al. (2007) Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 65: 982–987

    Article  Google Scholar 

  4. Poon RT et al. (2003) Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 52: 1768–1773

    Article  CAS  Google Scholar 

  5. Singh P et al. (2004) Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 60: 544–550

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. University of Pittsburgh and University of Pittsburgh Medical Center, PUH, Mezzanine 2, C Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA papachristoug@dom.pitt.edu

Authors and Affiliations

  1. GI Papachristou is an Assistant Professor of Medicine at the University of Pittsburgh, Pittsburgh, PA, USA.,

    Georgios I Papachristou

Authors
  1. Georgios I Papachristou
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papachristou, G. Should somatostatin or gabexate be given for prophylaxis of pancreatitis in patients undergoing ERCP?. Nat Rev Gastroenterol Hepatol 5, 14–15 (2008). https://doi.org/10.1038/ncpgasthep0996

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0996

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing